北海康成制药有限公司（股票代码：01228）于2026年7月3日发布了截至2026年6月30日的证券变动月报表。报告显示，公司本月无新增普通股发行或库藏股变动，已发行股份总数维持在597,443,347股，库存股份数为0股，表明股份数目无变化。公司法定/注册股本依旧为5,000,000,000股，面值每股USD 0.00001，金额合计USD 50,000。
月报显示，6月内“首次公开发售后购股权计划”有128,357份股份期权因失效而减少，期末结存13,969,343份，尚无转换为新股或库藏股转让的记录，期末可能发行的股份数量为5,360,004股。根据“首次公开发售前股权激励计划”，本月底仍可能发行20,767,760股；“首次公开发售后受限制股份单位计划”在本月无可供发行份额变动。公司在报告期内确认，其已满足香港联交所就该类股份所要求的公众持股量规定，亦未发生购回或注销股份的情况。
公告最后由公司董事长薛群博士签署。根据本次披露，公司在2026年6月期间的股本维持不变，各项权益事务均受到香港联交所《上市规则》及相关法律法规的规范与监督。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.